Serum concentration of nitrotyrosine as indicator of disease progress in dogs with myxomatous mitral valve disease

Ju Hwan Bang, Jun Seok Park, Kyoung Won Seo, Kun Ho Song

Research output: Contribution to journalArticle

Abstract

Nitrotyrosine was found to be dependent on the severity of myxomatous mitral valve disease (MMVD). However, a correlation of serum nitrotyrosine concentration in dogs with MMVD and the progression of the disease has not been investigated. This study compared changes in serum nitrotyrosine concentration with the progression of MMVD. Nine client-owned dogs were recruited for the study. Dogs were classified by measuring the amount of regurgitation using echocardiography into mild, moderate, or severe MMVD groups. Serum nitrotyrosine concentration was measured by an enzyme-linked immunosorbent assay test. Serum nitrotyrosine concentration was significantly higher at 180 days than at 0 day (P < 0.05). However, serum nitrotyrosine concentration at 360 days was lower than that at 180 days (P < 0.05). Serum nitrotyrosine concentration at 540 days was lower than at 180 days (P < 0.05). There was no correlation between serum nitrotyrosine and left atrial to aortic root diameter ratio (LA/Ao ratio) (n = 33, R2 = 0.003, P = 0.759). Also, there was no correlation between serum nitrotyrosine and vertebral heart score (VHS) (n = 33, R2 = 0.026, P = 0.368) and left ventricular end-diastolic diameter, normalized for body weight by the formula (LVEDDN) (n = 33, R2 = 0.053, P = 0.196). The results of the study suggest that the progression of MMVD is correlated with changes in serum nitrotyrosine concentration, which shows potential for use as a cardiac biomarker which can be used to analyze the progression of disease in MMVD.

Original languageEnglish (US)
Pages (from-to)102-105
Number of pages4
JournalJournal of Veterinary Clinics
Volume36
Issue number2
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Fingerprint

dog diseases
Mitral Valve
Dogs
Serum
disease course
dogs
echocardiography
Disease Progression
aorta
3-nitrotyrosine
heart valve diseases
biomarkers
heart
enzyme-linked immunosorbent assay
body weight
Echocardiography
Biomarkers
Enzyme-Linked Immunosorbent Assay
Body Weight
testing

Keywords

  • Canine
  • INOS
  • LVEDDN
  • MMVD
  • Nitrotyrosine
  • Peroxynitrite

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Serum concentration of nitrotyrosine as indicator of disease progress in dogs with myxomatous mitral valve disease. / Bang, Ju Hwan; Park, Jun Seok; Seo, Kyoung Won; Song, Kun Ho.

In: Journal of Veterinary Clinics, Vol. 36, No. 2, 01.04.2019, p. 102-105.

Research output: Contribution to journalArticle

@article{05f93c97e65e4ce39f74baae625a5ea0,
title = "Serum concentration of nitrotyrosine as indicator of disease progress in dogs with myxomatous mitral valve disease",
abstract = "Nitrotyrosine was found to be dependent on the severity of myxomatous mitral valve disease (MMVD). However, a correlation of serum nitrotyrosine concentration in dogs with MMVD and the progression of the disease has not been investigated. This study compared changes in serum nitrotyrosine concentration with the progression of MMVD. Nine client-owned dogs were recruited for the study. Dogs were classified by measuring the amount of regurgitation using echocardiography into mild, moderate, or severe MMVD groups. Serum nitrotyrosine concentration was measured by an enzyme-linked immunosorbent assay test. Serum nitrotyrosine concentration was significantly higher at 180 days than at 0 day (P < 0.05). However, serum nitrotyrosine concentration at 360 days was lower than that at 180 days (P < 0.05). Serum nitrotyrosine concentration at 540 days was lower than at 180 days (P < 0.05). There was no correlation between serum nitrotyrosine and left atrial to aortic root diameter ratio (LA/Ao ratio) (n = 33, R2 = 0.003, P = 0.759). Also, there was no correlation between serum nitrotyrosine and vertebral heart score (VHS) (n = 33, R2 = 0.026, P = 0.368) and left ventricular end-diastolic diameter, normalized for body weight by the formula (LVEDDN) (n = 33, R2 = 0.053, P = 0.196). The results of the study suggest that the progression of MMVD is correlated with changes in serum nitrotyrosine concentration, which shows potential for use as a cardiac biomarker which can be used to analyze the progression of disease in MMVD.",
keywords = "Canine, INOS, LVEDDN, MMVD, Nitrotyrosine, Peroxynitrite",
author = "Bang, {Ju Hwan} and Park, {Jun Seok} and Seo, {Kyoung Won} and Song, {Kun Ho}",
year = "2019",
month = "4",
day = "1",
doi = "10.17555/jvc.2019.04.36.2.102",
language = "English (US)",
volume = "36",
pages = "102--105",
journal = "Journal of Veterinary Clinics",
issn = "1598-298X",
publisher = "Korean Society of Veterinary Clinics",
number = "2",

}

TY - JOUR

T1 - Serum concentration of nitrotyrosine as indicator of disease progress in dogs with myxomatous mitral valve disease

AU - Bang, Ju Hwan

AU - Park, Jun Seok

AU - Seo, Kyoung Won

AU - Song, Kun Ho

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Nitrotyrosine was found to be dependent on the severity of myxomatous mitral valve disease (MMVD). However, a correlation of serum nitrotyrosine concentration in dogs with MMVD and the progression of the disease has not been investigated. This study compared changes in serum nitrotyrosine concentration with the progression of MMVD. Nine client-owned dogs were recruited for the study. Dogs were classified by measuring the amount of regurgitation using echocardiography into mild, moderate, or severe MMVD groups. Serum nitrotyrosine concentration was measured by an enzyme-linked immunosorbent assay test. Serum nitrotyrosine concentration was significantly higher at 180 days than at 0 day (P < 0.05). However, serum nitrotyrosine concentration at 360 days was lower than that at 180 days (P < 0.05). Serum nitrotyrosine concentration at 540 days was lower than at 180 days (P < 0.05). There was no correlation between serum nitrotyrosine and left atrial to aortic root diameter ratio (LA/Ao ratio) (n = 33, R2 = 0.003, P = 0.759). Also, there was no correlation between serum nitrotyrosine and vertebral heart score (VHS) (n = 33, R2 = 0.026, P = 0.368) and left ventricular end-diastolic diameter, normalized for body weight by the formula (LVEDDN) (n = 33, R2 = 0.053, P = 0.196). The results of the study suggest that the progression of MMVD is correlated with changes in serum nitrotyrosine concentration, which shows potential for use as a cardiac biomarker which can be used to analyze the progression of disease in MMVD.

AB - Nitrotyrosine was found to be dependent on the severity of myxomatous mitral valve disease (MMVD). However, a correlation of serum nitrotyrosine concentration in dogs with MMVD and the progression of the disease has not been investigated. This study compared changes in serum nitrotyrosine concentration with the progression of MMVD. Nine client-owned dogs were recruited for the study. Dogs were classified by measuring the amount of regurgitation using echocardiography into mild, moderate, or severe MMVD groups. Serum nitrotyrosine concentration was measured by an enzyme-linked immunosorbent assay test. Serum nitrotyrosine concentration was significantly higher at 180 days than at 0 day (P < 0.05). However, serum nitrotyrosine concentration at 360 days was lower than that at 180 days (P < 0.05). Serum nitrotyrosine concentration at 540 days was lower than at 180 days (P < 0.05). There was no correlation between serum nitrotyrosine and left atrial to aortic root diameter ratio (LA/Ao ratio) (n = 33, R2 = 0.003, P = 0.759). Also, there was no correlation between serum nitrotyrosine and vertebral heart score (VHS) (n = 33, R2 = 0.026, P = 0.368) and left ventricular end-diastolic diameter, normalized for body weight by the formula (LVEDDN) (n = 33, R2 = 0.053, P = 0.196). The results of the study suggest that the progression of MMVD is correlated with changes in serum nitrotyrosine concentration, which shows potential for use as a cardiac biomarker which can be used to analyze the progression of disease in MMVD.

KW - Canine

KW - INOS

KW - LVEDDN

KW - MMVD

KW - Nitrotyrosine

KW - Peroxynitrite

UR - http://www.scopus.com/inward/record.url?scp=85071391442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071391442&partnerID=8YFLogxK

U2 - 10.17555/jvc.2019.04.36.2.102

DO - 10.17555/jvc.2019.04.36.2.102

M3 - Article

AN - SCOPUS:85071391442

VL - 36

SP - 102

EP - 105

JO - Journal of Veterinary Clinics

JF - Journal of Veterinary Clinics

SN - 1598-298X

IS - 2

ER -